ERBB2,HER2: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It's the GeneMedi's summary page for Target/Biomarker Introduction of HER2,ERBB2. The page also collects GeneMedi's different modalities and formats products for HER2 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the HER2 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized. [provided by RefSeq, Jul 2008]

Pre-made HER2-specific INN-index biosimilar (antibody&conjugates)-cinrebafusp alfa, Gancotamab, Zanidatamab, zanidatamab zovodotin, Runimotamab, Margetuximab, Disitamab, Pertuzumab, Timigutuzumab, Fidasimtamab, Anbenitamab, tezatabep matraxetan, trastuzumab beta, Trastuzumab, trastuzumab emtansine, Marstacimab, trastuzumab duocarmazine, Zenocutuzumab, disitamab vedotin, Coprelotamab, ertumaxomab, trastuzumab deruxtecan

Anti-HER2 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.	Products Name (INN Index)	INN Name	Previous Name	Target	Format	Order
GMP-Bios-INN-780	Pre-Made Cinrebafusp Alfa P Alfaiosimilar, Bispecific, Anti-ERBB2/HER2;TNFRSF9 Antibody: Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;ILA/4-1BB/CDw137 therapeutic antibody	cinrebafusp alfa		ERBB2/HER2;TNFRSF9	Bispecific
GMP-Bios-ab-230	Pre-Made Gancotamab biosimilar, scFv, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody	Gancotamab		ERBB2/HER2	scFv
GMP-Bios-ab-639	Pre-Made Zanidatamab biosimilar, Bispecific mAb, Anti-ERBB2/HER2;ERBB2/HER2 Antibody: Anti-CD340/HER-2/MLN 19/NEU/NGL/TKR1/VSCN2;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody	Zanidatamab		ERBB2/HER2;ERBB2/HER2	Bispecific/biparatopic
GMP-Bios-INN-1055	Pre-Made Zanidatamab Zovodotin B Zovodotiniosimilar, Bispecific/Biparatopic, Anti-ERBB2/HER2;ERBB2/HER2 Therapeutic/Biparatopic Antibody Antibody: Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2	zanidatamab zovodotin		ERBB2/HER2;ERBB2/HER2	Bispecific/biparatopic
GMP-Bios-ab-500	Pre-Made Runimotamab biosimilar, Bispecific mAb, Anti-ERBB2/HER2;CD3E Antibody: Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;T3E/TCRE/IMD18 therapeutic antibody	Runimotamab		ERBB2/HER2;CD3E	Bispecific mAb
GMP-Bios-ab-335	Pre-Made Margetuximab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody	Margetuximab		ERBB2/HER2	Whole mAb
GMP-Bios-ab-148	Pre-Made Disitamab biosimilar, Whole mAb ADC, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody	Disitamab		ERBB2/HER2	Whole mAb ADC
GMP-Bios-ab-439	Pre-Made Pertuzumab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody	Pertuzumab		ERBB2/HER2	Whole mAb
GMP-Bios-ab-576	Pre-Made Timigutuzumab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody	Timigutuzumab		ERBB2/HER2	Whole mAb
GMP-Bios-ab-667	Pre-Made Fidasimtamab biosimilar, Whole mAb, Anti-PDCD1/PD-1;ERBB2/HER2 Antibody: Anti-CD279/PD1/SLEB2/hSLE1;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody	Fidasimtamab		PDCD1/PD-1;ERBB2/HER2	Bispecific Whole mAb
GMP-Bios-ab-023	Pre-Made Anbenitamab biosimilar, Bispecific mAb: Anti-ERBB2 (Domain II);ERBB2 (Domain IV) therapeutic antibody	Anbenitamab		ERBB2 (Domain II);ERBB2 (Domain IV)	Bispecific/biparatopic
GMP-Bios-INN-1021		tezatabep matraxetan		ERBB2	Radiolabelled peptide
GMP-Bios-INN-1030	Pre-Made Trastuzumab Beta Biosimilar, Whole Mab, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2/c-ERB-2/c-ERB2 therapeutic antibody	trastuzumab beta		ERBB2/HER2	Whole  mAb
GMP-Bios-ab-593	Pre-Made Trastuzumab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody	Trastuzumab		ERBB2/HER2	Whole mAb
GMP-Bios-INN-1033	Pre-Made Trastuzumab Emtansine Biosimilar, Whole Mab Adc, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2/c-ERB-2/c-ERB2 therapeutic antibody Drug Conjugate	trastuzumab emtansine		ERBB2/HER2	Whole mAb ADC
GMP-Bios-ab-336	Pre-Made Marstacimab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody	Marstacimab		ERBB2/HER2	Whole mAb
GMP-Bios-INN-1032	Pre-Made Trastuzumab Duocarmazine Biosimilar, Whole Mab Adc, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2/c-ERB-2/c-ERB2 therapeutic antibody Drug Conjugate	trastuzumab duocarmazine		ERBB2/HER2	Whole mAb ADC
GMP-Bios-ab-645	Pre-Made Zenocutuzumab biosimilar, Bispecific mAb, Anti-ERBB3/Erbb-3;ERBB2/HER2 Antibody: Anti-FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody	Zenocutuzumab		ERBB3/Erbb-3;ERBB2/HER2	Bispecific mAb
GMP-Bios-INN-804	Pre-Made Disitamab Vedotin Biosimilar, Whole Mab Adc, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2/c-ERB-2/c-ERB2 therapeutic antibody Drug Conjugate	disitamab vedotin		ERBB2/HER2	Whole mAb ADC
GMP-Bios-ab-119	Pre-Made Coprelotamab biosimilar, Whole mAb, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody	Coprelotamab		ERBB2/HER2	Whole mAb
GMP-Bios-INN-845	Pre-Made Ertumaxomab Biosimilar, Bispecific, Anti-Cd3E;Erbb2 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody	ertumaxomab		CD3E;ERBB2	Bispecific
GMP-Bios-INN-1031	Pre-Made Trastuzumab Deruxtecan Biosimilar, Whole Mab Adc, Anti-ERBB2/HER2 Antibody: Anti-CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2/c-ERB-2/c-ERB2 therapeutic antibody Drug Conjugate	trastuzumab deruxtecan		ERBB2/HER2	Whole mAb ADC

Pre-made anti-HER2 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-HER2 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-HER2 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cat No.	Antibody Name	Format	Classified by tag	Order
GM-Tg-hg-T14597-Ab	Anti-HER2/ERBB2 monoclonal antibody	mab	Biofunctional antibody, Therapeutics Target antibody, Diagnostic target antibody, Cytokine antibody